Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Market Size Estimates For The Anemia Drugs Market?

Over the past few years, the anemia drugs market has seen substantial growth. Its size is projected to increase from $14.72 billion in 2024 to $15.77 billion in 2025, representing a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this growth during the historic period include a higher incidence of chronic illnesses, increased awareness about iron deficiency anemia, a growing elderly population, improved healthcare accessibility in developing areas, and a surge in demand for targeted treatment strategies.

The market for anemia drugs is anticipated to exhibit robust growth in the upcoming years, expanding to “$21.09 billion by 2029 with a compound annual growth rate (CAGR) of 7.5%. This projected growth during the forecast period is connected to several factors such as the heightened acceptance of personalized medicine, increasing healthcare spending in emerging markets, a growing number of clinical trials for anemia treatments, a rise in the global incidences of anemia, and a ramped-up focus on developing drugs that center around patients’ needs. Notable trends for the forecast period encompass advancements in gene therapy aimed at anemia, improved delivery systems for iron supplements, innovations in erythropoiesis-stimulating agents, enhanced tools for detecting anemia, and breakthroughs in oral treatments for anemia.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24141&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Anemia Drugs Market?

The burgeoning emphasis on personalized medicine is anticipated to spur the expansion of the anemia drugs market. Personalized medicine represents an approach to healthcare and treatment that is adapted to the genetic profile, lifestyle, and environment of each patient. The mounting attention to personalization in medicine is due to progresses in genomic sequencing, enabling the accurate delineation of individual genetic differences related to disease and response to treatment. Personalized medicine bolsters the production of anemia drugs by facilitating treatments tailored to individual genetic characteristics, enhancing drug effectiveness, and reducing unpleasant side effects for enhanced patient outcomes. For example, the Personalized Medicine Coalition, a non-profit institution based in the US, stated in February 2024 that in 2023, the U.S. Food and Drug Administration (FDA) gave its approval to 16 new personalized treatments for patients with rare diseases. This is a significant leap from only 6 approvals in 2022. Consequently, the growing interest in personalized medicine is a driving force behind the growth of the anemia drugs market.

Which Sub-Segments Are Driving Growth Within The Anemia Drugs Market?

The anemia drugs market covered in this report is segmented –

1) By Drug Type: Dietary Supplements, Medicines

2) By Therapy Type: Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy, Other Therapy Types

3) By Anemia Type: Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, Others Anemia Type

4) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

5) By End-User: Clinic, Healthcare, Home Healthcare

Subsegments:

1) By Dietary Supplements: Iron Supplements, Vitamin B12 Supplements, Folic Acid Supplements, Multivitamin And Mineral Supplements

2) By Medicines: Erythropoiesis-Stimulating Agents (ESAs), Iron Chelating Agents, Corticosteroids, Immunosuppressants, Luspatercept And Related Agents

What Future-Focused Trends Are Anticipated In The Anemia Drugs Market?

Leading firms in the anemia drugs market are zeroing in on the development of innovative medicines, like oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors) to boost iron metabolism and ramp up the production of red blood cells for advanced anemia care. Oral HIF-PHI are oral drugs that aim at and limit the function of prolyl hydroxylase enzymes, integral in controlling the hypoxia-inducible factor (HIF) pathway. As an example, in February 2023, the UK-based pharmaceutical enterprise, GSK plc, introduced Jesduvroq. This treatment, designed to enhance red blood cell production and manage anemia in adults suffering from chronic kidney disease, is a part of the novel anemia drug system. It emphasizes superior iron metabolism, augmented red blood cell production, and individualized treatment methods. Jesduvroq proves to be highly effective in increasing red blood cell production and managing anemia in patients with chronic kidney disease, by promoting better iron metabolism, leading to improved treatment results.

Which Companies Hold A Competitive Edge In The 611 Market?

Major companies operating in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, Regen Biopharma Inc., BioLineRx Ltd., Bluebird Bio Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anemia-drugs-global-market-report

Which Region Dominates The Anemia Drugs Market Today?

North America was the largest region in the anemia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24141&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model